How to Cite
Abstract
Heart failure (HF) is a frequent clinical syndrome that represents the terminal stage of several heart diseases and is a serious public health problem. The prevalence of HF in the adult population worldwide is worrisome. It has been seen that the development and use of certain medications have decreased the morbidity and mortality of patients in addition to improving their quality of life. Currently, research has been conducted with very positive results with treatments such as the dual neprilysin inhibitor and the angiotensin receptor.
Keywords
References
Marino J. Consenso de insuficiencia cardíaca crónica. REVISTA ARGENTINA DE CARDIOLOGÍA [Internet]. 2016 [cited 10 October 2019];:5,6. Available from: https://www.sac.org.ar/wp-content/uploads/2016/10/consenso-de-insuficiencia-cardiaca-cronica-2016-1.pdf
King JB, Shah RU, Bress AP, Nelson RE, Bellows BK. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure. 2016 05;4(5):392-402. https://doi.org/10.1016/j.jchf.2016.02.007
Speranza Sánchez M, Quesada Chaves D, Castillo Chaves G, Lainez Sánchez L, Mora Tumminelli L, Brenes Umaña C et al. 21páginaRev. CostarricenRegistro nacional de insuficiencia cardíaca de Costa Rica. El estudio RENAIC CR. REVISTA COSTARRICENSE DE CARDIOLOGÍA [Internet]. 2017 [cited 10 October 2019];:22. Available from: https://www.scielo.sa.cr/pdf/rcc/v19n1-2/1409-4142-rcc-19-1-2-21.pdf
Speranza Sánchez M, Fernández González R, Araya Gómez V. Farmacoterapia de la insuficiencia cardíaca: análisis de casos de pacientes hospitalizados en un centro de salud privado en Costa Rica. REVISTA COSTARRICENSE DE CARDIOLOGÍA [Internet]. 2018 [cited 10 October 2019];:17. Available from: http://www.acc.co.cr/wp-content/uploads/2019/03/2018-v20-n2.pdf
Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, Greiner MA, Hammill BG, Hardy NC, Turner SJ, Laskey WK, Curtis LH, Hernandez AF, Mentz RJ, O’Brien EC. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure. 2017 04;5(4):305-309. https://doi.org/10.1016/j.jchf.2016.12.018
Heart Failure Guidelines. American Heart Association [Internet]. 2017 [cited 11 October 2019];:7. Available from: http://hfguidelines.ksw-gtg.com/publication/?i=451480#{%22issue_id%22:451480,%22page%22:0
Sánchez-Marteles M, Rubio Gracia J, Giménez López I. Fisiopatología de la insuficiencia cardiaca aguda: un mundo por conocer. Revista Clínica Española. 2016 01;216(1):38-46. https://doi.org/10.1016/j.rce.2015.09.010
Ponikowski P, Jankowska E. Patogenia y presentación clínica de la insuficiencia cardiaca aguda. Revista Española de Cardiología [Internet]. 2015 [cited 7 October 2019];68(4):331-337. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0300893215000603?via%3Dihub
https://doi.org/10.1016/j.recesp.2015.01.003
Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. European Heart Journal. 2012 08 31;34(12):886-893. https://doi.org/10.1093/eurheartj/ehs262
Wills B, Prada LP, Rincón A, Buitrago AF. Inhibición dual de la neprilisina y del receptor de la angiotensina (ARNI): una alternativa en los pacientes con falla cardiaca. Revista Colombiana de Cardiología. 2016 03;23(2):120-127. https://doi.org/10.1016/j.rccar.2015.08.001
Castillo Chaves Gabriela, Cai Daniel, Solís Blanco Agustín. Implicaciones de los péptidos natriuréticos cardíacos en la insuficiencia cardíaca. Rev. costarric. cardiol [Internet]. 2003 Dec [cited 2019 Oct 30] ; 5( 3 ): 39-50. Available from: http://www.scielo.sa.cr/scielo.php?script=sci_arttext&pid=S1409-41422003000300008&lng=en.
Manito N, Desai A, Núñez J, Crespo M, Martínez-Sellés M, Calvo C et al. Sacubitrilo/valsartán: una nueva referencia en el tratamiento de la insuficiencia cardiaca con fracción de eyección reducida. Sociedad Española de Cardiología [Internet]. 2017 [cited 5 October 2019];5. Available from: https://secardiologia.es/images/publicaciones/libros/sacubitrilo-valsartan-en-el-tratamiento-de-la-ic-con-fe-reducida-2017.pdf
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine. 2014 09 11;371(11):993-1004. https://doi.org/10.1056/nejmoa1409077
Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. New England Journal of Medicine. 2019 02 07;380(6):539-548. https://doi.org/10.1056/nejmoa1812851
Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, Rouleau JL, Zile MR, McMurray JJV, Solomon SD. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology. 2016 09 01;1(6):666. https://doi.org/10.1001/jamacardio.2016.1747
Jhund PS, Fu M, Bayram E, Chen C, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal. 2015 07 31;36(38):2576-2584. https://doi.org/10.1093/eurheartj/ehv330
Morales-Parra MP, Salazar-Niño JF, Caycedo-González LA, González-Torres DV, Jaramillo-Jaramillo M, Buitrago-Sandoval AF, González-Robledo G. Experiencia con sacubitril/valsartán en una clínica de falla cardiaca. Revista Colombiana de Cardiología. 2019 03;. https://doi.org/10.1016/j.rccar.2018.10.009
Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD, . Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. European Journal of Heart Failure. 2016 06 10;18(10):1228-1234. https://doi.org/10.1002/ejhf.580
Hsiao F, Wang C, Chang P, Lu Y, Huang C, Chu P. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan. Journal of Cardiovascular Pharmacology and Therapeutics. 2019 09 12;:107424841987295. https://doi.org/10.1177/1074248419872958
Januzzi JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Piña IL, Rocha RA, Shah AM, Williamson KM, Solomon SD, . Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019 09 17;322(11):1085. https://doi.org/10.1001/jama.2019.12821
Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, Greiner MA, Hammill BG, Hardy NC, Turner SJ, Laskey WK, Curtis LH, Hernandez AF, Mentz RJ, O’Brien EC. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure. 2017 04;5(4):305-309. https://doi.org/10.1016/j.jchf.2016.12.018
Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJ. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal. 2017 02 01;38(15):1132-1143. https://doi.org/10.1093/eurheartj/ehw570
Khariton Y, Fonarow GC, Arnold SV, Hellkamp A, Nassif ME, Sharma PP, Butler J, Thomas L, Duffy CI, DeVore AD, Albert NM, Patterson JH, Williams FB, McCague K, Spertus JA. Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure. 2019 Nov;7(11):933-941. https://doi.org/10.1016/j.jchf.2019.05.016
Solomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen H, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2019 Oct 24;381(17):1609-1620. https://doi.org/10.1056/nejmoa1908655